- Home
- CANF vs BBIO Comparison
CANF vs BBIO Comparison
Compare CANF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | BBIO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 14.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CANF | BBIO |
|---|---|---|
| Price | $0.18 | $76.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 21 |
| Target Price | $3.25 | ★ $76.24 |
| AVG Volume (30 Days) | 1.0M | ★ 1.9M |
| Earning Date | 02-03-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $560,000.00 | ★ $353,780,000.00 |
| Revenue This Year | $461.72 | $128.44 |
| Revenue Next Year | N/A | $76.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $0.23 | $26.55 |
| 52 Week High | $2.33 | $78.44 |
Technical Indicators
Market Signals| Indicator | CANF | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 22.66 | 65.57 |
| Support Level | $0.26 | $75.82 |
| Resistance Level | $0.30 | $78.44 |
| Average True Range (ATR) | 0.02 | 2.25 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 3.41 | 76.39 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.